Relay Therapeutics Hits New 52-Week High of $17.46, Up 108.5%

Relay Therapeutics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 17.46 on June 2, 2026. This achievement marks a remarkable increase of 108.5% over the past year, significantly outperforming the S&P 500, which has seen a gain of 28.2% during the same period. As a small-cap company in the Pharmaceuticals & Biotechnology industry, Relay Therapeutics has a market capitalization of USD 1,810 million. Despite its recent stock performance, the company remains in a loss-making position, with a return on equity of -48.97%. The stock's price-to-book ratio stands at 2.98, indicating how the market values the company's equity relative to its book value. Investors may note that the stock's 52-week low was recorded at USD 2.98, highlighting the significant growth it has experienced over the past year. This upward trend reflects the company's evolving market position within the competitive landscape of the biotechnology sector.